Seqker Biosciences
Personalized cancer vaccines, built on genomics
Seqker Biosciences is advancing personalized cancer immunotherapy through the development of neoantigen vaccines and the computational genomics that power them. Our mission is to make immunotherapy truly personal, designing treatments around the unique biology of each patient's tumor.
- Lead program
- SQK01Personalized neoantigen cancer vaccine in clinical development
- Platform
- HeliosAI-driven platform that identifies and designs patient-specific therapies
- Focus
- Precision oncologyPersonalized cancer vaccines and precision tumor profiling
- Partnerships
- WorldwideCollaborating with industry partners, research and clinical teams
Our team

Boyang Zhao, PhD
Co-Founder & CEO
Dr. Boyang Zhao leads the company's strategy, its SQK01 neoantigen vaccine program and the development of the Helios computational genomics platform. He brings 15 years of experience in oncology R&D and AI-driven drug discovery. Previously, he has held a number of scientific and leadership roles, including venture-backed healthcare startups, a $4.6B oncology biotech, and an $88B global bank. He holds a PhD from MIT.
Our multidisciplinary team brings together the expertise needed to advance personalized cancer vaccines at every stage of development.
- Bioinformatics & engineering
- Preclinical R&D
- Clinical development
- Clinical operations
- Manufacturing
- Regulatory
Our experience
Our team has trained and worked at leading universities, research institutes, and companies, across oncology, immunology, genomics and drug development.
Previous affiliations
- MIT
- Caltech
- UC Berkeley
- UCLA
- UCSF
- Massachusetts General Hospital
- NIH
- Chulalongkorn University
- Mahidol University
- Osaka University
- UCL
- ARIAD Pharmaceuticals
- MSD
- Vir Biotechnology
- Life Technologies
- ING
Work with us
Interested in partnering with Seqker, learning more about our technology, or exploring genomic services? We'd welcome the opportunity to connect.





